CVE-2015-3965

Description

Hospira Symbiq Infusion System 3.13 and earlier allows remote authenticated users to trigger "unanticipated operations" by leveraging "elevated privileges" for an unspecified call to an incorrectly exposed function.

Category

8.8
CVSS
Severity: High
CVSS 3.0 •
CVSS 2.0 •
EPSS 0.46%
Third-Party Advisory us-cert.gov
Affected: Hospira Symbiq Infusion System
Published at:
Updated at:

References

Link Tags
https://ics-cert.us-cert.gov/advisories/ICSA-15-174-01 third party advisory us government resource

Frequently Asked Questions

What is the severity of CVE-2015-3965?
CVE-2015-3965 has been scored as a high severity vulnerability.
How to fix CVE-2015-3965?
To fix CVE-2015-3965, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2015-3965 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2015-3965 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2015-3965?
CVE-2015-3965 affects Hospira Symbiq Infusion System.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.